Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

McKesson
Harvard Business School
Boehringer Ingelheim
Colorcon
Merck
Dow

Last Updated: June 29, 2022

AEMCOLO Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Aemcolo, and when can generic versions of Aemcolo launch?

Aemcolo is a drug marketed by Redhill and is included in one NDA. There are four patents protecting this drug.

This drug has twenty-seven patent family members in twenty countries.

The generic ingredient in AEMCOLO is rifamycin sodium. There are eleven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the rifamycin sodium profile page.

DrugPatentWatch® Generic Entry Outlook for Aemcolo

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be May 3, 2025. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Try it Free

Summary for AEMCOLO
International Patents:27
US Patents:4
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 21
Clinical Trials: 2
Patent Applications: 3,482
Drug Prices: Drug price information for AEMCOLO
What excipients (inactive ingredients) are in AEMCOLO?AEMCOLO excipients list
DailyMed Link:AEMCOLO at DailyMed
Drug patent expirations by year for AEMCOLO
Drug Prices for AEMCOLO

See drug prices for AEMCOLO

DrugPatentWatch® Estimated Generic Entry Opportunity Date for AEMCOLO
Generic Entry Date for AEMCOLO*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET, DELAYED RELEASE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for AEMCOLO

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Bradley ConnorPhase 2
Bradley A. Connor, M.D.Phase 2
Hunter Holmes Mcguire Veteran Affairs Medical CenterPhase 2

See all AEMCOLO clinical trials

Pharmacology for AEMCOLO

US Patents and Regulatory Information for AEMCOLO

AEMCOLO is protected by four US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of AEMCOLO is See Plans and Pricing.

This potential generic entry date is based on patent See Plans and Pricing.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting AEMCOLO

Oral antimicrobial pharmaceutical compositions
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Oral antimicrobial pharmaceutical compositions
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Oral antimicrobial pharmaceutical compositions
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Oral antimicrobial pharmaceutical compositions
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF TRAVELERS' DIARRHEA CAUSED BY NON-INVASIVE STRAINS OF ESCHERICHIA COLI IN ADULTS

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Redhill AEMCOLO rifamycin sodium TABLET, DELAYED RELEASE;ORAL 210910-001 Nov 16, 2018 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Redhill AEMCOLO rifamycin sodium TABLET, DELAYED RELEASE;ORAL 210910-001 Nov 16, 2018 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Redhill AEMCOLO rifamycin sodium TABLET, DELAYED RELEASE;ORAL 210910-001 Nov 16, 2018 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Redhill AEMCOLO rifamycin sodium TABLET, DELAYED RELEASE;ORAL 210910-001 Nov 16, 2018 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for AEMCOLO

When does loss-of-exclusivity occur for AEMCOLO?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Austria

Patent: 2889
Estimated Expiration: See Plans and Pricing

Canada

Patent: 69683
Estimated Expiration: See Plans and Pricing

Patent: 28005
Estimated Expiration: See Plans and Pricing

China

Patent: 76685
Estimated Expiration: See Plans and Pricing

Patent: 1317826
Estimated Expiration: See Plans and Pricing

Croatia

Patent: 0080252
Estimated Expiration: See Plans and Pricing

Cyprus

Patent: 08196
Estimated Expiration: See Plans and Pricing

Denmark

Patent: 63339
Estimated Expiration: See Plans and Pricing

European Patent Office

Patent: 63339
Estimated Expiration: See Plans and Pricing

Patent: 94560
Estimated Expiration: See Plans and Pricing

Germany

Patent: 2005006278
Estimated Expiration: See Plans and Pricing

Hungary

Patent: 900037
Estimated Expiration: See Plans and Pricing

Italy

Patent: 20041295
Estimated Expiration: See Plans and Pricing

Japan

Patent: 26262
Estimated Expiration: See Plans and Pricing

Patent: 08163038
Estimated Expiration: See Plans and Pricing

Patent: 08503540
Estimated Expiration: See Plans and Pricing

Mexico

Patent: 06014698
Estimated Expiration: See Plans and Pricing

Poland

Patent: 63339
Estimated Expiration: See Plans and Pricing

Portugal

Patent: 63339
Estimated Expiration: See Plans and Pricing

Serbia

Patent: 581
Estimated Expiration: See Plans and Pricing

Slovenia

Patent: 63339
Estimated Expiration: See Plans and Pricing

South Africa

Patent: 0610577
Estimated Expiration: See Plans and Pricing

South Korea

Patent: 1157486
Estimated Expiration: See Plans and Pricing

Patent: 070028441
Estimated Expiration: See Plans and Pricing

Patent: 080059337
Estimated Expiration: See Plans and Pricing

Spain

Patent: 03255
Estimated Expiration: See Plans and Pricing

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering AEMCOLO around the world.

Country Patent Number Title Estimated Expiration
Japan 2008503540 See Plans and Pricing
World Intellectual Property Organization (WIPO) 2006003043 See Plans and Pricing
Japan 5026262 See Plans and Pricing
Poland 1763339 See Plans and Pricing
South Korea 20080059337 ORAL ANTIMICROBIAL PHARMACEUTICAL COMPOSITIONS See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for AEMCOLO

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1763339 C201930053 Spain See Plans and Pricing PRODUCT NAME: RIFAMICINA SV; NATIONAL AUTHORISATION NUMBER: 84120-DE/H/5379/001/DC; DATE OF AUTHORISATION: 20190628; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): PL 08637/0028; DATE OF FIRST AUTHORISATION IN EEA: 20181218
1763339 122019000048 Germany See Plans and Pricing PRODUCT NAME: RIFAMYCIN SV; NAT. REGISTRATION NO/DATE: 2200986.00.00 20190509; FIRST REGISTRATION: GB PL 08637/0028 20181218
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKinsey
McKesson
Johnson and Johnson
AstraZeneca
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.